Previous 10 | Next 10 |
BOSTON, MASSACHUSETTS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia, announces the reinitiation of ...
Palm Beach, FL – November 16, 2022 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has devastated the world and impacted millions of people… as a result, the demand for the creation of therapeutic treatments has increased due to the p...
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print PR Newswire Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of ...
The b ook contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. BOSTON, MASSACHUSETTS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (t...
ProLectin-M , a new class of oral an t i viral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19...
Journal article published specifies the use of the MDX Viewer as an early warning sign of negative oxygen balance for use in Acute Respiratory Deficiency Syndrome (ARDS). BOSTON, MASSACHUSETTS, April 03, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developme...
Company releases new COVID-19 slide deck on website. BOSTON, MASSACHUSETTS, March 31, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale ...
Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported. BOSTON, MASSACHUSETTS, March 30, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( OTCQB:BIXT ), announced today that it intends...
The viral inhibitor is a polysaccharide designed to block galectins BOSTON, MASSACHUSETTS, March 24, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( OTCQB:BIXT ), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a ...
Live Youtube Broadcast with Expert Panelists on March 26, 2020 in MediWeb Studios BOSTON, MASSACHUSETTS, March 12, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by deliver...
News, Short Squeeze, Breakout and More Instantly...
Bioxytran Inc Company Name:
BIXT Stock Symbol:
OTCMKTS Market:
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...